Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (1371)	5/15/1998 11:30:00 AM
From: David Bogdanoff	Read Replies (2) \| Respond to of 2173

To all; Seems like J&J has trouble evaluating diabetes companies/products. The FDA came down hard on ERGO in its unanimous turn down. One item I find troublesome is the fact that the FDA didn't like the patient population sample: they wanted more minorities. If there is one thing a company should get right in its studies is getting the patient population right, even if it is more difficult to select some populations. Not doing so jeopardizes the whole effort, as occurred in ERGO's case. IMO AMLN is now still in the horse race, and J&J has bet on a laggard. David